Safety and efficacy of transdermal buprenorphine for the relief of cancer pain

Naing, Cho, Aung, Kyan, Racloz, Vanessa and Yeoh, Peng Nam (2013) Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. Journal of Cancer Research and Clinical Oncology, 139 12: 1963-1970. doi:10.1007/s00432-013-1487-0


Author Naing, Cho
Aung, Kyan
Racloz, Vanessa
Yeoh, Peng Nam
Title Safety and efficacy of transdermal buprenorphine for the relief of cancer pain
Journal name Journal of Cancer Research and Clinical Oncology   Check publisher's open access policy
ISSN 0171-5216
1432-1335
Publication date 2013-01-01
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1007/s00432-013-1487-0
Open Access Status Not Open Access
Volume 139
Issue 12
Start page 1963
End page 1970
Total pages 8
Place of publication Heidelberg, Germany
Publisher Springer
Language eng
Subject 1306 Cancer Research
2730 Oncology
Abstract Purpose: This study aimed to synthesize the available evidence on the efficacy and safety of transdermal (TD) buprenorphine. Methods: We searched studies in electronic databases. Randomized controlled trials (RCTs) assessing the efficacy of TD buprenorphine comparing with placebo or other comparator drug in relieving cancer pain were included. The primary end points are patient-reported pain intensity and pain relief. For dichotomous data, the summary relative risk (RR) and its 95 % confidence interval (CI) were derived using random-effect model in view of heterogeneity testing. Results: Eight clinical trials (n = 909) were included in the analysis. Only a few studies reported the same outcome in similar way, which created difficulty in the pooling of outcome data. Two studies (n = 288) assessed 'responders' and showed a significant difference between TD buprenorphine and placebo in all three doses of TD buprenorphine, 35.5, 52.5, or 70 μg/h (RR 1.74, 95 % CI 1.31-2.32; I 2 0 %); the numbers-needed-to-treat was 5.8 (3.9-11). Two studies (n = 331) showed a comparable requirement for rescue SL buprenorphine between TD buprenorphine and placebo (RR 1.25, 95 % CI 0.84-1.88; I 2 0 %). The preferred outcome measure '50 % pain relief' was not reported in any included studies. On the basis of summary quality, further research is likely to have an important impact on our confidence in the estimate. Conclusion: Transdermal buprenorphine has an increasing role for the relief of cancer pain. Further research in this field is needed. Multicentre studies in this field using a common protocol and strict supervision will be more practicable.
Keyword Buprenorphine
Cancer
Pain
Transdermal
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 10 Dec 2013, 10:25:33 EST by System User on behalf of School of Public Health